TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 21106921

Group type: EXPERIMENTAL
Intervention: Whole pecans
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Blended pecans
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Whole and blended pecans pooled
Number of subjects: 16
Study: 20070133

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Psychotherapy (CBT)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Stepped Collaborative Care (CC)
Number of subjects: 0

Group type: COMPARATOR
Intervention: CC (Control)
Number of subjects: 0
Study: 17470831

Group type: EXPERIMENTAL
Intervention: Infliximab plus prednisone
Number of subjects: 51

Group type: COMPARATOR
Intervention: Placebo plus prednisone
Number of subjects: 51
Study: 15166683

Group type: EXPERIMENTAL
Intervention: Methylphenidate (0.3 mg/kg/dose, twice a day)
Number of subjects: 34
Study: 11669586

Group type: EXPERIMENTAL
Intervention: Ultrasound scans performed by the surgeon in Group 1 (n=213)
Number of subjects: 302

Group type: EXPERIMENTAL
Intervention: Ultrasound scans performed by the surgeon in Group 2 (n=231)
Number of subjects: 302

Group type: COMPARATOR
Intervention: USS examination by radiologists in Group 2 (n=231)
Number of subjects: 302
Study: 9415946

Group type: COMPARATOR
Intervention: Normal sleep schedule (2300‐0700 hours)
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Partial sleep deprivation (0400‐0800 hours)
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Total sleep deprivation
Number of subjects: 3
Study: 8073358

Group type: EXPERIMENTAL
Intervention: Ultrasonic dissection
Number of subjects: 0
Study: 3129806

Group type: EXPERIMENTAL
Intervention: Lithium preparations (lithium carbonate, lithium oxybutyrate)
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: Cimetidine
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: Salbutamol
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: Verapamil
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 201

Group type: COMPARATOR
Intervention: Placebo and standard antiulcerative therapy
Number of subjects: 201
Study: 30079775

Group type: EXPERIMENTAL
Intervention: Diabetes Self-Efficacy Enhancing Program (DSEEP)
Number of subjects: 113

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 113
Study: 29126966

Group type: EXPERIMENTAL
Intervention: Densovirus infection
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High IG plant (Plantago lanceolata)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Low IG plant (P. major)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Surface sterilization to exclude microbes
Number of subjects: 0
Study: 28819835

Group type: EXPERIMENTAL
Intervention: Linagliptin
Number of subjects: 2681
Study: 26576944

Group type: EXPERIMENTAL
Intervention: 0.15 mmol/kg gadobutrol
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 0.10 mmol/kg gadobutrol
Number of subjects: 30

Group type: COMPARATOR
Intervention: 0.20 mmol/kg Gd‐DTPA
Number of subjects: 30
Study: 23207186

Group type: EXPERIMENTAL
Intervention: YGD (3 tablets)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: SFF (5g in 100ml water)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: YGD + SFF
Number of subjects: 58

Group type: COMPARATOR
Intervention: Placebo (water and placebo)
Number of subjects: 58
Study: 21545667

Group type: EXPERIMENTAL
Intervention: Monitoring and feedback plus counseling (TMC)
Number of subjects: 252

Group type: EXPERIMENTAL
Intervention: Monitoring and feedback (TM)
Number of subjects: 252

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 252
Study: 18629524

Group type: EXPERIMENTAL
Intervention: FREMS therapy
Number of subjects: 35

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 35
Study: 16582130

Group type: EXPERIMENTAL
Intervention: Misoprostol 800 mcg vaginally on study day 1, with a repeat dose if indicated on day 3.
Number of subjects: 485
Study: 12755982

Group type: EXPERIMENTAL
Intervention: Systemic sulodexide
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Systemic prednisone
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 30
Study: 10617948

Group type: EXPERIMENTAL
Intervention: Red wine
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Dealcoholized red wine
Number of subjects: 12

Group type: COMPARATOR
Intervention: Phenol-stripped red wine
Number of subjects: 12

Group type: COMPARATOR
Intervention: Water
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: All beverages
Number of subjects: 12
Study: 8858462

Group type: EXPERIMENTAL
Intervention: 400 mg i.v. at 8 hourly intervals (group 1 and 2)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: 400 mg i.v. at 12 hourly intervals (group 3)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: 300 mg i.v. at 12 hourly intervals (group 4)
Number of subjects: 42
Study: 1512337

Group type: EXPERIMENTAL
Intervention: Captopril (4 days of therapy)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study: 6437183

Group type: EXPERIMENTAL
Intervention: Iopamidol
Number of subjects: 27

Group type: COMPARATOR
Intervention: Methylglucamine iothalamate (Conray-60)
Number of subjects: 27
Study: 30328569

Group type: EXPERIMENTAL
Intervention: Shenzhu Guanxin Recipe Granules (SGR) 10 g/day for 12 weeks
Number of subjects: 184

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 184

Group type: EXPERIMENTAL
Intervention: Shenzhu Guanxin Recipe Granules (SGR)
Number of subjects: 184
Study: 30024973

Group type: EXPERIMENTAL
Intervention: Tension-Type Headache presenteeism
Number of subjects: 78
Study: 27583882

Group type: EXPERIMENTAL
Intervention: Collateral Meridian Therapy (CMT)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Local Tender Area Related Meridians (LTARM)
Number of subjects: 70
Study: 24889137

Group type: EXPERIMENTAL
Intervention: Powdered black tea solids (3 cups per day)
Number of subjects: 111

Group type: COMPARATOR
Intervention: Flavonoid-free flavour- and caffeine-matched placebo
Number of subjects: 111
Study: 22863159

Group type: EXPERIMENTAL
Intervention: Combination aliskiren/hydrochlorothiazide (HCT) 150/12.5 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Aliskiren 150 mg (force-titrated to 300/25 mg and 300 mg)
Number of subjects: 0
Study: 20582746

Group type: EXPERIMENTAL
Intervention: 2 mg/kg 0.2% ropivacaine
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: 0.5 mg/kg ketamine
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: 2 mg/kg 0.2% ropivacaine plus 0.5 mg/kg ketamine
Number of subjects: 45

Group type: COMPARATOR
Intervention: Group R (ropivacaine)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Group K (ketamine)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Group R+K (ropivacaine plus ketamine)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Group R+K
Number of subjects: 45
Study: 18765450

Group type: EXPERIMENTAL
Intervention: Paracetamol plus ibuprofen
Number of subjects: 0

Group type: COMPARATOR
Intervention: Paracetamol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ibuprofen
Number of subjects: 0
Study: 15914990

Group type: EXPERIMENTAL
Intervention: Calcium carbonate-based dentifrice
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Silica-based dentifrice
Number of subjects: 10

Group type: COMPARATOR
Intervention: Negative control
Number of subjects: 10
Study: 12908893

Group type: EXPERIMENTAL
Intervention: High-fat diet (HSAFA)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Low-fat diet (LSAFA)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: High-fat diet rich in unsaturated fatty acids (HUFA)
Number of subjects: 25
Study: 9813398

Group type: EXPERIMENTAL
Intervention: Rifaximin 200 mg t.i.d.
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Rifaximin (all doses)
Number of subjects: 72
Study: 9053413

Group type: EXPERIMENTAL
Intervention: Herbal eye drop preparation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Normal saline (placebo)
Number of subjects: 0
Study: 2550646

Group type: EXPERIMENTAL
Intervention: Enalapril (ACE inhibitor)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 972960

Group type: EXPERIMENTAL
Intervention: Monetary reward for successful performance
Number of subjects: 0

Group type: COMPARATOR
Intervention: No supplementary incentive
Number of subjects: 0
Study: 30301233

Group type: EXPERIMENTAL
Intervention: Moringa + CEN
Number of subjects: 360

Group type: EXPERIMENTAL
Intervention: Cricket + CEN
Number of subjects: 360

Group type: COMPARATOR
Intervention: CEN alone
Number of subjects: 360
Study: 28034999

Group type: EXPERIMENTAL
Intervention: Free snus for ad libitum use
Number of subjects: 543
Study: 26121788

Group type: EXPERIMENTAL
Intervention: Oral rehydration therapy (ORT) group, allowed to drink clear liquids until 2 hours before anesthesia induction
Number of subjects: 58

Group type: COMPARATOR
Intervention: Control group, fasted from 21:00 the night before surgery
Number of subjects: 58
Study: 23241727

Group type: EXPERIMENTAL
Intervention: 400 µg of misoprostol orally 12 hours before the procedure
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 21939942

Group type: EXPERIMENTAL
Intervention: Bivalirudin monotherapy
Number of subjects: 554

Group type: COMPARATOR
Intervention: Heparin plus glycoprotein IIb/IIIa inhibitor (GPI)
Number of subjects: 554

Group type: COMPARATOR
Intervention: Bare-metal stents (BMS)
Number of subjects: 554

Group type: COMPARATOR
Intervention: Drug-eluting stents (DES)
Number of subjects: 554
Study: 18652102

Group type: EXPERIMENTAL
Intervention: Bupivacaine (3 ml of isobaric bupivacaine 5 mg/ml)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Ropivacaine (3 ml of isobaric ropivacaine 5 mg/ml)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Levobupivacaine (3 ml of isobaric levobupivacaine 5 mg/ml)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 120
Study: 16710757

Group type: EXPERIMENTAL
Intervention: Amantadine sulphate
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control (n=14)
Number of subjects: 32
Study: 12599027

Group type: EXPERIMENTAL
Intervention: Open drainage system (secretion goes directly into the bandage)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Gravity drainage systems
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High-vacuum suction drainage
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Redon drainage
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Prophylactic drainage insertion in uncomplicated thyroid surgery and hernia repair
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Drainage insertion for up to 72 hours
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Routine microbiological examination of the tip of the drainage tube
Number of subjects: 0
Study: 11163674

Group type: EXPERIMENTAL
Intervention: Standard titre measles vaccine given at age 9 months
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Standard titre measles vaccine given at age 6 months
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both vaccine groups
Number of subjects: 0
Study: 9644284

Group type: EXPERIMENTAL
Intervention: Long foreperiod schedule
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Short foreperiod schedule
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Memorized condition (MM)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Nonmemorized condition (NM)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Overall foreperiod effect
Number of subjects: 6
Study: 7820191

Group type: EXPERIMENTAL
Intervention: Medrogestone (M) at a dose of 10 mg/day from D4 to D24
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control (Cycle 1)
Number of subjects: 10
Study: 2830642

Group type: EXPERIMENTAL
Intervention: Chemotherapy (cisplatin 70 mg/m2 i.v. day one, etoposide 100 mg/m2 i.v. day one, 200 mg/m2 orally days 2 and 3, repeated every third week to a maximum of 4 cycles)
Number of subjects: 234

Group type: COMPARATOR
Intervention: Radiotherapy (42 Gy given in 15 fractions over a 3-week period)
Number of subjects: 234
Study: 1385603

Group type: EXPERIMENTAL
Intervention: ondansetron (4 mg)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: amphetamine (15 mg)
Number of subjects: 9

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 9

Group type: COMPARATOR
Intervention: placebo/amphetamine (15 mg)
Number of subjects: 9
Study: 836481

Group type: EXPERIMENTAL
Intervention: Remotivation-Activities sequence
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Remotivation-only sequence
Number of subjects: 32

Group type: COMPARATOR
Intervention: Remotivation-Social Living sequence
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 32
Study: 30239152

Group type: EXPERIMENTAL
Intervention: Nutritional counseling intervention
Number of subjects: 106

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 106
Study: 28954882

Group type: EXPERIMENTAL
Intervention: Caffeine 200 mg BID for 6-18 months
Number of subjects: 121

Group type: COMPARATOR
Intervention: Placebo capsules for 6-18 months
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Caffeine 200 mg BID
Number of subjects: 121
Study: 23660738

Group type: EXPERIMENTAL
Intervention: PDT delivered twice within 1 week (group A)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: PDT delivered only once (group B)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Sham treatment without activating the laser (group C)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: PDT (both groups A and B)
Number of subjects: 28
Study: 23962145

Group type: EXPERIMENTAL
Intervention: Grade 1 [123I]FP-CIT SPECT scan
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Grade 2 [123I]FP-CIT SPECT scan
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Grade 3 [123I]FP-CIT SPECT scan
Number of subjects: 83

Group type: COMPARATOR
Intervention: Dopamine transporter uptake ratios
Number of subjects: 83
Study: 22545106

Group type: EXPERIMENTAL
Intervention: 1.7 g of DHA and 0.6 g EPA daily for 6 months
Number of subjects: 174

Group type: COMPARATOR
Intervention: Placebo for 6 months
Number of subjects: 174
Study: 19182454

Group type: EXPERIMENTAL
Intervention: Detrusitol
Number of subjects: 69

Group type: COMPARATOR
Intervention: Oxybutynin
Number of subjects: 69

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 69
Study: 17404558

Group type: EXPERIMENTAL
Intervention: Nasal intermittent positive pressure ventilation
Number of subjects: 88

Group type: COMPARATOR
Intervention: Nasal continuous positive airway pressure
Number of subjects: 88
Study: 15194015

Group type: EXPERIMENTAL
Intervention: Pl(A2) allele in smokers
Number of subjects: 592

Group type: COMPARATOR
Intervention: Pl(A2) allele
Number of subjects: 592
Study: 12108813

Group type: EXPERIMENTAL
Intervention: Multisystemic Therapy (MST)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Usual Community Services (Control)
Number of subjects: 80
Study: 9675649

Group type: EXPERIMENTAL
Intervention: Helicobacter pylori-positive group
Number of subjects: 37

Group type: COMPARATOR
Intervention: Helicobacter pylori-negative group
Number of subjects: 37
Study: 7995008

Group type: COMPARATOR
Intervention: Quinidine monotherapy
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Combination treatment of amiloride (1 mumol/L) and quinidine (10 mumol/L)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Combination treatment of amiloride and quinidine
Number of subjects: 10
Study: 2574728

Group type: EXPERIMENTAL
Intervention: Nisoldipine once daily
Number of subjects: 171

Group type: EXPERIMENTAL
Intervention: Nifedipine twice daily
Number of subjects: 171

Group type: EXPERIMENTAL
Intervention: Nisoldipine and Nifedipine combined with a beta-blocker
Number of subjects: 171

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 171
Study: 4892037

Group type: EXPERIMENTAL
Intervention: Nitrazepam (Mogadon)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Nitrazepam
Number of subjects: 27

Group type: COMPARATOR
Intervention: Butobarbitone
Number of subjects: 27
Study: 31108553

Group type: EXPERIMENTAL
Intervention: Planning competence training (PKT)
Number of subjects: 467

Group type: COMPARATOR
Intervention: Control groups (KG-B, KG-C, KG-D)
Number of subjects: 467
Study: 30689903

Group type: EXPERIMENTAL
Intervention: RYGB surgery after a 4-week low-calorie diet
Number of subjects: 19

Group type: COMPARATOR
Intervention: Standard medical treatment (control group)
Number of subjects: 19
Study: 28739538

Group type: EXPERIMENTAL
Intervention: Extended PE training (4-day workshop plus expert case consultation)
Number of subjects: 180

Group type: COMPARATOR
Intervention: Standard PE training (4-day workshop only)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Extended PE training
Number of subjects: 180

Group type: COMPARATOR
Intervention: Standard PE training
Number of subjects: 180
Study: 25440652

Group type: EXPERIMENTAL
Intervention: Percutaneous superior vena cava clamped drainage
Number of subjects: 0

Group type: COMPARATOR
Intervention: Percutaneous superior vena cava unclamped drainage
Number of subjects: 0
Study: 22623063

Group type: EXPERIMENTAL
Intervention: Hamstrings plus Cocker‐Arnold procedure (group B)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Hamstrings (control group A)
Number of subjects: 60
Study: 22256771

Group type: EXPERIMENTAL
Intervention: Shuxuetong injection
Number of subjects: 80

Group type: COMPARATOR
Intervention: Routine treatment (Control)
Number of subjects: 80
Study: 19826110

Group type: EXPERIMENTAL
Intervention: Bevacizumab plus cisplatin and etoposide
Number of subjects: 63
Study: 16169159

Group type: EXPERIMENTAL
Intervention: Motivational interviewing (MI) techniques integrated into the initial contact and evaluation session
Number of subjects: 423

Group type: COMPARATOR
Intervention: Standard intake/evaluation session
Number of subjects: 423

Group type: EXPERIMENTAL
Intervention: Motivational interviewing (MI) techniques
Number of subjects: 423

Group type: COMPARATOR
Intervention: Standard intervention
Number of subjects: 423
Study: 15467219

Group type: COMPARATOR
Intervention: Sho-hange-ka-bukuryo-to
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nichin-to
Number of subjects: 0

Group type: COMPARATOR
Intervention: Zingiberis Rhizoma
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pinelliae Tuber
Number of subjects: 0
Study: 10792124

Group type: EXPERIMENTAL
Intervention: 10- to 14-day therapies
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: 14-day therapies
Number of subjects: 13

Group type: COMPARATOR
Intervention: 7-day therapies
Number of subjects: 13

Group type: COMPARATOR
Intervention: 10-day therapies
Number of subjects: 13
Study: 9213839

Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 80

Group type: COMPARATOR
Intervention: Propofol
Number of subjects: 80
Study: 1530319

Group type: EXPERIMENTAL
Intervention: Intra-arterial infusion chemotherapy (I.A.)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Systemic chemotherapy (I.V.)
Number of subjects: 70
Study: 4018470

Group type: EXPERIMENTAL
Intervention: Isosorbide‐5‐mononitrate (IS‐5‐MN; 40 mg orally)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Sustained-release Isosorbide dinitrate (SRDI; 40 mg orally)
Number of subjects: 18
Study: 30797848

Group type: EXPERIMENTAL
Intervention: 6-0 Fast Absorbing Gut (FG)
Number of subjects: 0

Group type: COMPARATOR
Intervention: 5-0 Fast Absorbing Gut (FG)
Number of subjects: 0
Study: 29076978

Group type: EXPERIMENTAL
Intervention: Transcutaneous Electrical Acupoint Stimulation (TEAS)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 75
Study: 28708766

Group type: EXPERIMENTAL
Intervention: Open-label placebo with rationale (OPR)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Deceptive placebos (DP)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Open-label placebo without rationale (OPR‐)
Number of subjects: 160

Group type: COMPARATOR
Intervention: No treatment (NT)
Number of subjects: 160
Study: 25748442

Group type: EXPERIMENTAL
Intervention: 5‐MTHF (5 mM) administered locally via intradermal microdialysis in older adults.
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Folic acid (5 mg/day) supplementation for 6 weeks in older adults.
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo control for 6 weeks in older adults.
Number of subjects: 22
Study: 23863960

Group type: EXPERIMENTAL
Intervention: CLEAR regimen (oral levofloxacin, ethambutol, azithromycin, and rifampin)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo regimen
Number of subjects: 30
Study: 20886402

Group type: EXPERIMENTAL
Intervention: Large-capacity forceps (2.2-mm forceps, Radial jaw3)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Standard forceps (1.8-mm forceps, FB-39Q)
Number of subjects: 32
Study: 19121185

Group type: EXPERIMENTAL
Intervention: Red cell volume-based transfusion guideline (group RCV)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Standard haemoglobin concentration-based departmental policy (group C)
Number of subjects: 86
Study: 15979246

Group type: EXPERIMENTAL
Intervention: Lifetime history of drug treatment
Number of subjects: 153

Group type: COMPARATOR
Intervention: No history of drug treatment
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: Craving drugs at least 15 days in the past month
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: Using cocaine at least 15 days in the past month
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: ASI alcohol composite score
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: Perceived seriousness of legal problems
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: History of at least 3 pregnancies
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: History of physical abuse by a known person
Number of subjects: 153
Study: 14588178

Group type: EXPERIMENTAL
Intervention: VATS lung biopsy
Number of subjects: 100

Group type: COMPARATOR
Intervention: Open lung biopsy
Number of subjects: 100
Study: 10672720

Group type: EXPERIMENTAL
Intervention: Forlax (Beaufour Ipsen, France)
Number of subjects: 0
Study: 8839602

Group type: EXPERIMENTAL
Intervention: Hypertensive, hypervolemic, hemodilutional therapy (HT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 1750429

Group type: EXPERIMENTAL
Intervention: Aluminum hydroxide-containing antacid (113 mg per tablet, 2 tablets four times daily)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Placebo tablets
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Aluminum hydroxide-containing antacid
Number of subjects: 56
Study: 6976617

Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid (Aspirin), 3000 mg daily
Number of subjects: 12

Group type: COMPARATOR
Intervention: Fluproquazone, 300 mg daily
Number of subjects: 12